FinGad is a Place to Review Strategies With Fellow Investors
Not a member yet?
Not a member yet?
|
michael's review
Investment Sector: IPO / Secondary Offering Submitted by Michael 
, Director of Engineering
at Auctoritas
7 months ago Tags: Merck Drugs Vioxx Add Tag |
Vioxx Verdict Against Merck Reversed
[ Login to Propose An Edit ]
Today the state appellate court overturned a multimillion dollar verdict involving Vioxx, ruling that there is not sufficient evidence linking it to a heart attack suffered by the plaintiff's spouse.
It's interesting that different courts are coming up with different rulings. On April 2006, a jury found Merck liable and awarded $32 million in damages. That amount was later reduced to $7.75 million.
This in my view makes investing in pharmaceutical companies very difficult. Not only that the courts fluctute in opinions, there are jurors without medical degrees who are coming up with the results, and hence make these companies extremely unstable.
Your thoughts are welcome.
Did you find this article useful?
Add Review to: 
